Alessa Therapeutics ("Alessa"), a clinical-stage biopharmaceutical company advancing novel localized drug delivery technology ...

Discover how High-Intensity Focused Ultrasound (HIFU) treatment is revolutionizing care for prostate cancer and tumours with ...

DelveInsight's Castration-sensitive Prostate Cancer Market Insights report includes a comprehensive understanding of current treatment practices, CSPC emerging drugs, market share of individual ...

The American Cancer Society supported five bills aimed at cancer prevention and treatment in 2025, but only one passed.

Researchers have identified chromosomal instability in circulating tumour cells as a prognostic and predictive biomarker in ...

ETX-19477 is a potent, selective inhibitor of poly (ADP-ribose) glycohydrolase (PARG), an enzyme that plays a role in the DNA ...

A Comprehensive OverviewThe global Peptide Cancer Vaccine Market is valued at USD 1.2 Billion in 2025 and is projected to reach a value of USD 15.72 Billion by 2035 at a CAGR (Compound Annual Growth ...

Plans to seek regulatory approval to commence a Phase III trial in the US and Canada VANCOUVER, BC, Jan. 8, 2026 /PRNewswire/ -- Sustained Therapeutics Inc. ("Sustained Therapeutics" or the "Company") ...

Q2 2026 Earnings Call Transcript January 6, 2026 AngioDynamics, Inc. misses on earnings expectations. Reported EPS is ...

Silex Systems' failure to receive large amounts of funding from the most recent DOE awards disappointed investors. Read why ...

Discover the serious yet rare side effects of Ozempic, including pancreatitis, thyroid cancer, and more, plus expert insights ...

The deal brings Dark Blue's preclinical oncology products, including an MLLT1/3-targeted agent for leukemias, into Amgen's portfolio.